AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
A new study by researchers at Ireland's Maynooth University, based on patient data gathered by the US-based Michael J. Fox Foundation, found that an overwhelming 84% of patients with Parkinson's ...
Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.
Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale - MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity ...
Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...
Stockhead on MSN17h
Health Check: Alterity angles for fast-track FDA approval after positive trial results tackling Parkinson’s-like disorderAlterity plans to seek US FDA fast-track approval after posting positive phase II results for multiple system atrophy ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company with a market capitalization of $3.06 billion, focuses on developing and commercializing innovative medicines to address unmet ...
Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating ...
A new EPA ban on TCE, a common industrial cleaning agent and contaminant, begins this year. UCSF’s Samuel Goldman, who led groundbreaking research to link TCE to Parkinson’s Disease, talks about the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback